Ingenza Ltd

Belkins
Ingenza: The Industrial Biotechnology Company with a broad customer base across the chemicals, pharmaceuticals, food, feed and fuel industries.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

LILLY, VIR BIOTECHNOLOGY AND GSK COLLABORATES TO EVALUATE A COMBINATION OF TWO COVID-19 THERAPIES IN LOW-RISK PATIENTS

Lilly | January 28, 2021

news image

Eli Lilly and Company, Vir Biotechnology, Inc. also, GlaxoSmithKline plc declares a collaboration effort to assess a mix of two COVID-19 therapies in low-risk patients with mild to direct COVID-19. Lilly has extended its progressing BLAZE-4 trial to assess the organization of bamlanivimab (LY-CoV555) 700mg with VIR-7831 (otherwise called GSK4182136) 500mg, two killing antibodies that quandary to various epitopes of the SARS-CoV-2 spike protein. This unique collaboration effort denotes the first ...

Read More

MEDTECH

FLAMINGO THERAPEUTICS EXPANDS ALLIANCE WITH IONIS PHARMACEUTICALS TO DEVELOP RNA-TARGETED THERAPIES FOR ONCOLOGY

Flamingo Therapeutics, Inc. | September 09, 2021

news image

Flamingo Therapeutics, Inc., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that it has entered into an agreement with Ionis Pharmaceuticals to develop RNA-targeted therapies to treat various forms of cancer. This alliance is an expansion of an existing collaboration with Ionis on the FLAME™ discovery engine, following Flamingo's Series A financing in 2020. The agreement and discovery alliance will leverage Flamingo's de...

Read More

A FUTURE GENE THERAPY COULD BE DELIVERED IN TINY ‘NANOCONTAINERS’

Labiotech.eu | January 28, 2020

news image

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....

Read More

GOLDENBIOTECH'S NEW DRUG ANTROQUINONOL RECEIVES FDA APPROVAL ON COVID-19 PHASE 2 CLINICAL TRIAL IN USA

Golden Biotechnology Corp. | July 02, 2020

news image

Golden Biotechnology Corp. (GoldenBiotech, 4132.TWO), a leading Taiwanese biopharmaceutical company, announced that the FDA approved its investigational new drug (IND) application for a Phase II clinical trial of Antroquinonol (Hocena®) on COVID-19 patients in USA. GoldenBiotech has also applied for the US BARDA (Biomedical Advanced Research and Development Administration) CoronaWatch meeting. Future developmental planning of Antroquinonol in COVID-19 include joining the COVID-19 Candidate a...

Read More
news image

MEDICAL

LILLY, VIR BIOTECHNOLOGY AND GSK COLLABORATES TO EVALUATE A COMBINATION OF TWO COVID-19 THERAPIES IN LOW-RISK PATIENTS

Lilly | January 28, 2021

Eli Lilly and Company, Vir Biotechnology, Inc. also, GlaxoSmithKline plc declares a collaboration effort to assess a mix of two COVID-19 therapies in low-risk patients with mild to direct COVID-19. Lilly has extended its progressing BLAZE-4 trial to assess the organization of bamlanivimab (LY-CoV555) 700mg with VIR-7831 (otherwise called GSK4182136) 500mg, two killing antibodies that quandary to various epitopes of the SARS-CoV-2 spike protein. This unique collaboration effort denotes the first ...

Read More
news image

MEDTECH

FLAMINGO THERAPEUTICS EXPANDS ALLIANCE WITH IONIS PHARMACEUTICALS TO DEVELOP RNA-TARGETED THERAPIES FOR ONCOLOGY

Flamingo Therapeutics, Inc. | September 09, 2021

Flamingo Therapeutics, Inc., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that it has entered into an agreement with Ionis Pharmaceuticals to develop RNA-targeted therapies to treat various forms of cancer. This alliance is an expansion of an existing collaboration with Ionis on the FLAME™ discovery engine, following Flamingo's Series A financing in 2020. The agreement and discovery alliance will leverage Flamingo's de...

Read More
news image

A FUTURE GENE THERAPY COULD BE DELIVERED IN TINY ‘NANOCONTAINERS’

Labiotech.eu | January 28, 2020

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....

Read More
news image

GOLDENBIOTECH'S NEW DRUG ANTROQUINONOL RECEIVES FDA APPROVAL ON COVID-19 PHASE 2 CLINICAL TRIAL IN USA

Golden Biotechnology Corp. | July 02, 2020

Golden Biotechnology Corp. (GoldenBiotech, 4132.TWO), a leading Taiwanese biopharmaceutical company, announced that the FDA approved its investigational new drug (IND) application for a Phase II clinical trial of Antroquinonol (Hocena®) on COVID-19 patients in USA. GoldenBiotech has also applied for the US BARDA (Biomedical Advanced Research and Development Administration) CoronaWatch meeting. Future developmental planning of Antroquinonol in COVID-19 include joining the COVID-19 Candidate a...

Read More